Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.2K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.2K
Hypersensitivities01:30

Hypersensitivities

7.8K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.8K
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

36
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
36
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

40
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
40
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

58
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
58
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

43
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
43

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical impact of allergy and pre-medication in CT studies with low-osmolality intravenous iodinated contrast media.

Clinical radiology·2022
Same author

Combined immunodeficiency (CVID and CD4 lymphopenia) is associated with a high risk of malignancy among adults with primary immune deficiency

Clinical and experimental immunology·2021
Same author

γδT Cells Are Essential for Orthodontic Tooth Movement.

Journal of dental research·2021
Same author

Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation.

Clinical and experimental immunology·2020
Same author

Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association.

Lupus·2020
Same author

The diagnostic value of 14-3-3η protein levels in patients with rheumatoid arthritis.

Best practice & research. Clinical rheumatology·2019

Related Experiment Video

Updated: Feb 21, 2026

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.1K

Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience.

Y Tal1, R Maoz Segal2, P Langevitz3,4

  • 11 Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Lupus
|October 11, 2017
PubMed
Summary

Hydroxychloroquine (HCQ) desensitization effectively treats hypersensitivity skin reactions in systemic lupus erythematosus (SLE) patients. This protocol allows continued use of HCQ, a vital medication for managing SLE.

Keywords:
HydroxychloroquinePlaquenildesensitizationpregnancysystemic lupus erythematosus

More Related Videos

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

3.6K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

583

Related Experiment Videos

Last Updated: Feb 21, 2026

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.1K
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

3.6K
Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

583

Area of Science:

  • Rheumatology
  • Immunology
  • Dermatology

Background:

  • Hydroxychloroquine (HCQ) is a cornerstone therapy for autoimmune/rheumatic diseases like systemic lupus erythematosus (SLE).
  • Its immune-modulating properties are crucial for maintaining SLE remission and managing clinical manifestations.
  • HCQ is generally considered safe for long-term use and during pregnancy, making it a recommended treatment for most SLE patients.

Purpose of the Study:

  • To evaluate the efficacy of a novel two-stage oral desensitization protocol for hydroxychloroquine (HCQ).
  • To assess the protocol's ability to overcome mild to moderate late hypersensitivity skin reactions in SLE patients.
  • To explore the potential mechanisms underlying HCQ desensitization.

Main Methods:

  • A two-stage oral desensitization protocol was developed and implemented.
  • The protocol was administered to patients experiencing hypersensitivity skin reactions to HCQ.
  • Patient outcomes and tolerance to desensitization were monitored.

Main Results:

  • The HCQ desensitization protocol was successfully implemented in 12 out of 13 patients.
  • The protocol effectively managed mild to moderate late hypersensitivity skin reactions.
  • Prolonged oral desensitization demonstrated efficacy in enabling continued HCQ therapy.

Conclusions:

  • Hydroxychloroquine desensitization is a viable and effective strategy for managing hypersensitivity reactions in SLE patients.
  • This approach facilitates the continued use of essential HCQ treatment.
  • Further research into the mechanisms of HCQ desensitization is warranted.